Since diabetes is an important component of NAFLD development and metabolic syndrome, the efficacy, safety and good tolerability make the GLP-1 agonist a suitable treatment tool for NAFLD. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.